Given that μ opioid (MOP) and canabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to associate as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacologic effects has been raised. As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo. Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer. Antinociceptive testing in mice revealed 5 to be the most potent member of the series. As neither a mixture of monovalent ligands 9 + 10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.
Given that μ opioid (MOP) and canabinoid (n class="Gene">CB1) receptors are colocalized in various regions of the central nervous system and have been reported to associate as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacologic effects has been raised. As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo. Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer. Antinociceptive testing in mice revealed 5 to be the most potent member of the series. As neither a mixture of monovalent ligands 9 + 10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.
Authors: David J Daniels; Natalie R Lenard; Chris L Etienne; Ping-Yee Law; Sandra C Roerig; Philip S Portoghese Journal: Proc Natl Acad Sci U S A Date: 2005-12-19 Impact factor: 11.205
Authors: Ivone Gomes; Mohammed Akli Ayoub; Wakako Fujita; Werner C Jaeger; Kevin D G Pfleger; Lakshmi A Devi Journal: Annu Rev Pharmacol Toxicol Date: 2015-10-22 Impact factor: 13.820
Authors: Cody J Lensing; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano Journal: J Med Chem Date: 2018-05-09 Impact factor: 7.446
Authors: Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano Journal: J Med Chem Date: 2016-03-29 Impact factor: 7.446